A child may survive a brain tumor and still face a second, less visible threat from the treatment itself: acute kidney injury, or AKI. A new retrospective study published in Pediatric Research examines how often this complication occurs during pediatric brain-tumor treatment and what it may mean for survivors later in life. The study, led by H.J. Knickel, E.J. Rompies and K.A. Krallman and colleagues, focuses on a population whose long-term health is increasingly recognized as an essential part of cancer care. As survival rates improve, researchers are looking beyond tumor control to understand how chemotherapy, surgery, radiation and intensive supportive treatments can affect organs that may not be the primary target of the disease.
AKI is a sudden decline in the kidneys’ ability to filter blood, regulate fluid balance and maintain the body’s chemical stability. Clinically, it is often identified through a rise in serum creatinine, a waste product normally removed by the kidneys, and through changes in urine output. The injury can develop over hours or days and may be reversible, but it is not always harmless. Even when kidney function appears to recover, an episode of AKI can leave lasting biological changes, including reduced filtration capacity, altered blood-pressure regulation and increased susceptibility to chronic kidney disease. In children, the concern is especially important because an injured kidney must support the body for decades after the original illness has been treated.
The kidneys can be placed under pressure by nearly every phase of complex cancer therapy. Certain chemotherapeutic agents can damage the tubular cells responsible for reabsorbing water and electrolytes. Other medicines may alter blood flow within the kidney or trigger inflammatory reactions. Neurosurgical procedures can be accompanied by blood loss, fluctuations in blood pressure or the need for prolonged intensive-care support, all of which can reduce renal perfusion. Children may also receive contrast agents for imaging, antimicrobial drugs for infections, diuretics, anticonvulsants and medications required to control swelling around the brain. Each exposure may be manageable on its own, but the combined physiological burden can make the kidneys vulnerable.
Brain tumors present a particularly challenging setting for studying AKI because treatment is rarely limited to a single intervention. Patients may undergo surgery followed by radiation and several cycles of chemotherapy, sometimes while coping with seizures, neurological deficits, nutritional problems or infections. Fluid management is also delicate: clinicians must avoid dehydration, which can reduce kidney blood flow, while preventing excessive fluid accumulation that could worsen cerebral swelling or respiratory function. In intensive care, even short periods of low blood pressure or systemic inflammation can influence renal function. The new analysis places these overlapping risks within the longer trajectory of childhood cancer survivorship.
Rather than following a single treatment episode in real time, the investigators conducted a retrospective analysis of survivors. This approach allows researchers to examine medical records and reconstruct whether AKI occurred during cancer treatment, how it was recognized and how patients progressed afterward. Retrospective studies cannot establish cause and effect as firmly as prospective clinical trials, because the available records may differ in completeness and patients may have received different combinations of therapies. They can, however, reveal patterns that are difficult to detect during the acute phase of illness. By returning to the treatment histories of survivors, the study connects an event that may have been viewed as temporary with the possibility of consequences extending well beyond hospital discharge.
The scientific importance of the work lies in its focus on an organ system that can be overshadowed by the urgency of treating a brain tumor. During a life-threatening diagnosis, attention understandably centers on removing or controlling the tumor and protecting neurological function. Kidney injury may appear secondary, particularly if laboratory values improve before the child leaves the hospital. Yet serum creatinine is an imperfect and sometimes delayed indicator of renal damage. A substantial reduction in filtration may occur before creatinine rises, especially in children with low muscle mass or changing nutritional status. This means that some episodes of kidney stress may be missed unless clinicians interpret laboratory results alongside urine output, fluid balance, medication exposure and the patient’s overall condition.
For survivors, the implications extend into routine medical care. A child who experienced AKI may benefit from periodic monitoring of blood pressure, serum creatinine, estimated glomerular filtration rate and urine protein. In selected cases, clinicians may use additional tests to evaluate tubular function or detect subtle changes in renal reserve. These assessments can be particularly relevant during later illnesses, when fever, vomiting, dehydration or new medications may place renewed stress on the kidneys. Survivorship programs traditionally monitor for recurrence, endocrine complications, neurocognitive effects, hearing loss and cardiac toxicity associated with cancer therapy. The study’s subject supports a broader model in which kidney health is included as a deliberate part of long-term follow-up rather than assessed only when symptoms become obvious.
The findings also raise questions about prevention. Before treatment begins, clinicians could document baseline kidney function, hydration status and prior renal disease, creating a reference point for interpreting later changes. During therapy, medication doses may need adjustment according to filtration capacity, while potentially nephrotoxic drugs can be avoided or replaced when clinically feasible. Careful fluid management, rapid treatment of infection and close attention to blood pressure may reduce avoidable injury. Newer biomarkers, including molecules released during tubular stress, are being investigated because they may identify damage earlier than conventional creatinine testing. Such tools are not yet a substitute for established clinical measurements, but they could eventually help distinguish a transient laboratory fluctuation from an evolving renal injury.
The study also highlights why pediatric kidney outcomes should be evaluated over time rather than at a single endpoint. Children are still growing, and the kidneys must adapt to changing body size, muscle mass and metabolic demands. A modest loss of renal function that seems clinically insignificant in the short term could become more consequential during adolescence or adulthood, particularly if accompanied by hypertension or proteinuria. Conversely, many children with treatment-associated AKI may recover well when the episode is recognized promptly and managed effectively. Long-term research is therefore needed to determine which patients remain at greatest risk, whether specific tumor types or treatment combinations are associated with more severe injury and how kidney outcomes intersect with overall quality of life.
By examining AKI among survivors of pediatric brain tumors, Knickel, Rompies, Krallman and their colleagues bring attention to a complication that can disappear from view once the immediate cancer crisis has passed. The message is not that kidney injury is inevitable, nor that successful tumor treatment should be judged primarily through renal outcomes. It is that survival is a continuing medical process, and every organ affected during therapy may shape the future health of the child. Integrating kidney surveillance into pediatric oncology could help clinicians identify damage earlier, protect remaining renal function and give families a clearer picture of the health risks that may persist after treatment. As more children live long-term after brain cancer, understanding and preventing these hidden consequences will become an increasingly important measure of medical success.
Subject of Research: Acute kidney injury during the treatment of pediatric brain tumors and its significance among survivors.
Article Title: Acute kidney injury during treatment of pediatric brain tumors: a retrospective analysis of survivors.
Article References: Knickel, H.J., Rompies, E.J., Krallman, K.A. et al. “Acute kidney injury during treatment of pediatric brain tumors: a retrospective analysis of survivors.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05344-2
Image Credits: AI Generated
DOI: 10.1038/s41390-026-05344-2
Keywords: acute kidney injury, pediatric brain tumors, childhood cancer, cancer survivors, nephrotoxicity, chemotherapy, kidney health, pediatric oncology, long-term outcomes
Tags: chemotherapy-related kidney damagechild brain tumor treatment complicationseffects of intensive cancer therapies on renal functionimpact of tumor treatment on kidney functionkidney health monitoring in childhood cancerkidney injury biomarkers in childrenlong-term health of childhood cancer survivorspediatric acute kidney injurypediatric supportive care in cancer treatmentradiation therapy kidney risksretrospective studies on pediatric AKIsurvival outcomes and organ toxicity
